Suchergebnisse - (Subject:"Siltuximab")

PubPharm (18)

1

Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease

enthalten in: Blood advances | 2022

von van Rhee, F. | Rosenthal, A. | Kanhai, K. | +4

2

Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab

enthalten in: British journal of haematology | 2021

von van Rhee, F. | Rossi, J. | Simpson, D. | +10

3

Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease

enthalten in: American journal of hematology | 2020

von Fajgenbaum, D. | Wu, D. | Goodman, A. | +21

4

Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease : a prespecified, open-label, extension analysis of two trials

enthalten in: The Lancet. Haematology | 2020

von van Rhee, F. | Casper, C. | Voorhees, P. | +4

5

Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease : secondary analyses of phase II clinical trial data

enthalten in: British journal of haematology | 2019

von Morra, D. | Pierson, S. | Shilling, D. | +6

6

Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma : an open-label phase I trial

enthalten in: Blood cancer journal | 2016

von Shah, J. | Feng, L. | Thomas, S. | +8

7

A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease

enthalten in: Oncotarget | 2015

von van Rhee, F. | Casper, C. | Voorhees, P. | +7

8

A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma

enthalten in: American journal of hematology | 2015

von Orlowski, R. | Gercheva, L. | Williams, C. | +17

9

A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndrome

enthalten in: American journal of hematology | 2014

von Garcia-Manero, G. | Gartenberg, G. | Steensma, D. | +7

10

Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma

enthalten in: Blood | 2014

von San-Miguel, J. | Bladé, J. | Shpilberg, O. | +18

ErratumIn: Blood. 2014 Aug 14;124(7):1201